HemaCare Corporation (OTCMKTS: HEMA) is a long-standing leader in the customization and supply of human-derived biological products and services for biomedical research and cell therapy. Within the U.S. and internationally, the company is well-known for its network of FDA-registered, GMP/GTP-compliant collection centers where it collects human biological materials. Types of cellular materials collected and supplied by Hemacare include peripheral blood, bone marrow, and cord blood, each of which it isolates into primary cells types and can supply to customers in both fresh and frozen states. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
The Market for Cord Blood and Tissue Banking in China
China represents a unique and compelling market for cord blood and tissue banking. First, the Chinese government only supports one cord blood bank within each of the provinces. Specifically, the Chinese government issues one cord blood banking license per province, and the licensed company must function as hybrid “public and private” bank.
The private, for-profit division of the company is expected to fund the company’s public, donation-based division, because no government support is given to support its processing and storage of donated units.
In this article:
Arizona-based biotech startup BioLab Sciences announces patent for regenerative tissue therapy, MyOwn Skin™
SCOTTSDALE, Ariz., Oct. 24, 2018 — BioLab Sciences, an innovator in regenerative medicine technologies, today announced its exclusively licensed technology for MyOwn SkinTM, a painless, non-surgical procedure, which leverages a patient’s own skin to produce full-thickness skin grafts in 5-7 days.
MyOwn SkinTM is a revolutionary approach that uses a patient’s own skin to accelerate healing of chronic wounds, burns, diabetic foot ulcers and other difficult-to-heal wounds. By utilizing a small skin sample, this regenerative approach allows the body to heal itself and is less likely to face infection or rejection. [Read more…]
CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank
CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR). According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”
The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.
With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.
[Read more…]
Cryo-Cell Acquires CORD:USE for $14 Million, Enters Public Cord Blood Sector
On June 4, 2018, Cryo-Cell International announced it will be acquiring the hybrid public-private cord blood bank CORD:USE for $14 million. The acquisition’s purposes are to strengthen its cord blood banking services by entering the public cord blood sector and to solidify its role as an industry leader. Learn about the combined commercial entity of Cryo-Cell CORD:USE below.
Cryo-Cell CORD:USE | The Acquisition of CORD:USE
In this article:
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 62
- Next Page »